Day: December 13, 2024

Windstream Will Use the Net Proceeds to Redeem All of its 7.750% Senior First Lien Notes due 2028 LITTLE ROCK, Ark., Dec. 12, 2024 (GLOBE NEWSWIRE) — Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) today announced the pricing of $1.4 billion aggregate principal amount of additional 8.250% Senior First Lien Notes due 2031 (the “Additional Windstream Notes”) by Windstream Services, LLC and Windstream Escrow Finance Corp. (collectively, the “Windstream Co-Issuers”), each a subsidiary of Windstream Holdings II, LLC (“Windstream”). The Additional Windstream Notes will constitute a further issuance of the Windstream Co-Issuers’ 8.250% Senior First Lien Notes due 2031, which were issued on October 4, 2024. The offering of the Additional Windstream Notes is expected to close on December 23, 2024, subject to customary closing conditions. The...

NEVADA, Dec. 12, 2024 (GLOBE NEWSWIRE) — Mountain Lake Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 21,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Stock Market LLC (“Nasdaq”) and begin trading tomorrow, December 13, 2024, under the ticker symbol “MLACU.” Each unit consists of one Class A ordinary share and one right. Each right entitles the holder thereof to receive one-tenth (1/10) of one Class A ordinary share upon the consummation of an initial business combination. A right holder must hold ten rights to receive one Class A ordinary share at the closing of the initial business combination. Once the securities constituting the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on Nasdaq...

IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) — CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the pricing of its public offering of 8,000,000 shares of its common stock, 7,300,000 of which are being offered by CG Oncology and 700,000 of which are being offered by an existing stockholder of CG Oncology, each at a public offering price of $28.00 per share. The gross proceeds to CG Oncology from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $204.4 million. CG Oncology will not receive proceeds from the sale of shares of its common stock by the selling stockholder. The offering...

Geneva, Switzerland, Dec. 12, 2024 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 7,692,308 ordinary shares at a public offering price of $1.30, for gross proceeds of $10.0 million (the “Offering”), before deducting commissions and offering expenses. Maxim Group LLC is acting as the sole placement agent for the Offering. SEALSQ currently intends to utilize the net proceeds from the Offering to fund the deployment of its next-generation post-quantum semiconductor technology and ASIC capabilities in the United States, to support working...

BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 1,367,521 units, with each unit consisting of one ordinary share (or prefunded warrant in lieu thereof) one Series A warrant to purchase one ordinary share, and one series B warrant to purchase one ordinary share for gross proceeds of approximately $8.0 million. Each unit is being sold at an effective offering price of $5.85 per unit, priced at-the-market under Nasdaq rules. Each Series A warrant will be immediately exercisable at an exercise price of $5.85 per share and will expire five years from the date of issuance. Each Series B warrant will be immediately...

BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) — LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a leading global biopharmaceutical company focused on the innovation and production of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Shenyang Municipal Public Security Bureau in China (the “Bureau”) has initiated criminal investigations into actions taken by former chairman of the board of directors Yi Zhang (“Former Chairman”). Investigation Details: The Company has uncovered evidence suggesting that Yi Zhang, during his tenure in key executive roles, misappropriated corporate assets for personal gain and mismanaged the Company, resulting in significant financial losses over past several years, thereby seriously harming the interests of shareholders of...

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$10 million milestone payment by its partner Takeda (TSE:4502/​NYSE:TAK). Takeda received a national reimbursement recommendation for FRUZAQLA® (fruquintinib) for patients with previously treated metastatic colorectal cancer (“CRC”) in Spain in December 2024, the first national reimbursement recommendation in Europe. CRC is the second most common cause of cancer-related...

MONCTON, New Brunswick, Dec. 12, 2024 (GLOBE NEWSWIRE) — Major Drilling Group International Inc. (“Major Drilling”), is pleased to announce the appointment of Ashley Martin as Chief Operating Officer (“COO”) of the Company, effective immediately. “I am happy to announce the promotion of Ashley into the newly created role of COO. This appointment is in line with our strategic focus on growth and innovation. Ashley has dedicated 30 years to the drilling industry, with the last 23 years focused on Major Drilling’s success. Throughout his career, he has excelled in various leadership roles, including General Manager of Canada and, more recently, Vice President of Operations – Latin America,” Mr. Denis Larocque, President & CEO of Major Drilling said. As COO, Mr. Martin will work closely with recently appointed Chief Technology...